Your browser doesn't support javascript.
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar, Zachary A; Beam, Elena; O'Horo, John C; Seville, Maria Teresa; Brumble, Lisa; Ganesh, Ravindra; Razonable, Raymund R.
  • Yetmar ZA; Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Beam E; Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • O'Horo JC; Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Seville MT; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Brumble L; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA.
  • Ganesh R; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
  • Razonable RR; Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Transpl Infect Dis ; 24(4): e13901, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-2008758
ABSTRACT

BACKGROUND:

Solid organ transplant recipients (SOTRs) are at high-risk for severe infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-spike monoclonal antibodies are currently utilized under emergency use authorization to prevent hospitalization in high-risk individuals with coronavirus disease 2019 (COVID-19), including SOTRs. However, clinical data for bebtelovimab, the sole currently available anti-spike monoclonal antibody for COVID-19, is limited.

METHODS:

We conducted a retrospective cohort study of adult SOTRs diagnosed with mild-to-moderate COVID-19 from January 2022 through May 2022 who received either bebtelovimab or sotrovimab. The primary outcome was COVID-19-related hospitalization within 30 days of COVID-19 diagnosis. Data were analyzed with Fisher's exact test.

RESULTS:

Among 361 SOTRs, 92 (25.5%) received bebtelovimab and 269 (74.5%) received sotrovimab. The most common organ transplant was a kidney (42.4%). SOTRs who received bebtelovimab had a higher proportion who had received a booster SARS-CoV-2 vaccine dose and had received their last vaccination dose more recently. Eleven (3.0%) SOTRs were hospitalized, and rates of hospitalization were similar between monoclonal antibody groups (3.3% versus 3.0%; p > .99). Three patients required admission to an intensive care unit, all of who received sotrovimab. Four (1.1%) patients died within 30 days of COVID-19 diagnosis, two from each group.

CONCLUSIONS:

SOTRs with mild-to-moderate COVID-19 who received bebtelovimab had similar rates of COVID-19-related hospitalization as those who received sotrovimab. While differences in vaccination rates and viral subvariants could act as confounders, bebtelovimab appears to be of similar effectiveness as sotrovimab.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Organ Transplantation / COVID-19 Drug Treatment Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Humans Language: English Journal: Transpl Infect Dis Journal subject: Transplantation Year: 2022 Document Type: Article Affiliation country: Tid.13901

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Organ Transplantation / COVID-19 Drug Treatment Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Humans Language: English Journal: Transpl Infect Dis Journal subject: Transplantation Year: 2022 Document Type: Article Affiliation country: Tid.13901